Oct 19

Τεχνικά κατασκευασμένος ιός που δόθηκε με 3,7εκατομμύρια ενίσχυση από τις ΗΠΑ στη WUHAN να τον αναπτύξει και εξαπολύσει από τον Antony Fauci και Σια.

By Γεώργιος Ευαγγελάτος in Επιστήμη

Όμως το Nature Medicine διαφωνεί, είναι αποτέλεσμα μεταλλάξεων από ζώο (νυχτερίδα) και μόλυνσης του ανθρώπου παρά τεχνητής τροποποίησης.

The proximal origin of SARS-CoV-2

Published: 17 March 2020

Nature Medicine volume 26, pages 450–452 (2020)Cite this article

Metrics details

To the Editor — Since the first reports of novel pneumonia (COVID-19) in Wuhan, Hubei province, China^1,2, there has been considerable discussion on the origin of the causative virus, SARS-CoV-2³ (also referred to as HCoV-19)⁴. Infections with SARS-CoV-2 are now widespread, and as of 11 March 2020, 121,564 cases have been confirmed in more than 110 countries, with 4,373 deaths⁵.

SARS-CoV-2 is the seventh coronavirus known to infect humans; SARS-CoV, MERS-CoV and SARS-CoV-2 can cause severe disease, whereas HKU1, NL63, OC43 and 229E are associated with mild symptoms⁶. Here we review what can be deduced about the origin of SARS-CoV-2 from comparative analysis of genomic data. We offer a perspective on the notable features of the SARS-CoV-2 genome and discuss scenarios by which they could have arisen. Our analyses clearly show that SARS-CoV-2 is not a laboratory construct or a purposefully manipulated virus.

Notable features of the SARS-CoV-2 genome

Our comparison of alpha- and betacoronaviruses identifies two notable genomic features of SARS-CoV-2: (i) on the basis of structural studies^7,8,9 and biochemical experiments^1,9,10, SARS-CoV-2 appears to be optimized for binding to the human receptor ACE2; and (ii) the spike protein of SARS-CoV-2 has a functional polybasic (furin) cleavage site at the S1–S2 boundary through the insertion of 12 nucleotides⁸, which additionally led to the predicted acquisition of three O-linked glycans around the site.

1. Mutations in the receptor-binding domain of SARS-CoV-2

The receptor-binding domain (RBD) in the spike protein is the most variable part of the coronavirus genome^1,2. Six RBD amino acids have been shown to be critical for binding to ACE2 receptors and for determining the host range of SARS-CoV-like viruses⁷. With coordinates based on SARS-CoV, they are Y442, L472, N479, D480, T487 and Y4911, which correspond to L455, F486, Q493, S494, N501 and Y505 in SARS-CoV-2⁷. Five of these six residues differ between SARS-CoV-2 and SARS-CoV (Fig. 1a). On the basis of structural studies^7,8,9 and biochemical experiments^1,9,10, SARS-CoV-2 seems to have an RBD that binds with high affinity to ACE2 from humans, ferrets, (νυφίτσες), cats and other species with high receptor homology⁷.

**Fig. 1: Features of the spike protein in human SARS-CoV-2 and related coronaviruses.**

While the analyses above suggest that SARS-CoV-2 may bind human ACE2 with high affinity, computational analyses predict that the interaction is not ideal⁷ and that the RBD sequence is different from those shown in SARS-CoV to be optimal for receptor binding^7,11. Thus, the high-affinity binding of the SARS-CoV-2 spike protein to human ACE2 is most likely the result of natural selection on a human or human-like ACE2 that permits another optimal binding solution to arise. This is strong evidence that SARS-CoV-2 is not the product of purposeful manipulation.

2. Polybasic furin cleavage site and O-linked glycans

The second notable feature of SARS-CoV-2 is a polybasic cleavage site (RRAR) at the junction of S1 and S2, the two subunits of the spike⁸ (Fig. 1b). This allows effective cleavage by furin and other proteases and has a role in determining viral infectivity and host range¹². In addition, a leading proline is also inserted at this site in SARS-CoV-2; thus, the inserted sequence is PRRA (Fig. 1b). The turn created by the proline is predicted to result in the addition of O-linked glycans to S673, T678 and S686, which flank the cleavage site and are unique to SARS-CoV-2 (Fig. 1b). Polybasic cleavage sites have not been observed in related ‘lineage B’ betacoronaviruses, although other human betacoronaviruses, including HKU1 (lineage A), have those sites and predicted O-linked glycans¹³. Given the level of genetic variation in the spike, it is likely that SARS-CoV-2-like viruses with partial or full polybasic cleavage sites will be discovered in other species.

The functional consequence of the polybasic cleavage site in SARS-CoV-2 is unknown, and it will be important to determine its impact on transmissibility and pathogenesis in animal models. Experiments with SARS-CoV have shown that insertion of a furin cleavage site at the S1–S2 junction enhances cell–cell fusion without affecting viral entry¹⁴. In addition, efficient cleavage of the MERS-CoV spike enables MERS-like coronaviruses from bats to infect human cells¹⁵. In avian influenza viruses, rapid replication and transmission in highly dense chicken populations selects for the acquisition of polybasic cleavage sites in the hemagglutinin (HA) protein¹⁶, which serves a function similar to that of the coronavirus spike protein. Acquisition of polybasic cleavage sites in HA, by insertion or recombination, converts low-pathogenicity avian influenza viruses into highly pathogenic forms¹⁶. The acquisition of polybasic cleavage sites by HA has also been observed after repeated passage in cell culture or through animals¹⁷.

The function of the predicted O-linked glycans is unclear, but they could create a ‘mucin-like domain’ that shields epitopes or key residues on the SARS-CoV-2 spike protein¹⁸. Several viruses utilize mucin-like domains as glycan shields involved immunoevasion¹⁸. Although prediction of O-linked glycosylation is robust, experimental studies are needed to determine if these sites are used in SARS-CoV-2.

Theories of SARS-CoV-2 origins

It is improbable that SARS-CoV-2 emerged through laboratory manipulation of a related SARS-CoV-like coronavirus. As noted above, the RBD of SARS-CoV-2 is optimized for binding to human ACE2 with an efficient solution different from those previously predicted^7,11. Furthermore, if genetic manipulation had been performed, one of the several reverse-genetic systems available for betacoronaviruses would probably have been used¹⁹. However, the genetic data irrefutably show that SARS-CoV-2 is not derived from any previously used virus backbone²⁰. Instead, we propose two scenarios that can plausibly explain the origin of SARS-CoV-2: (i) natural selection in an animal host before zoonotic transfer; and (ii) natural selection in humans following zoonotic transfer. We also discuss whether selection during passage could have given rise to SARS-CoV-2.

1. Natural selection in an animal host before zoonotic transfer

As many early cases of COVID-19 were linked to the Huanan market in Wuhan^1,2, it is possible that an animal source was present at this location. Given the similarity of SARS-CoV-2 to bat SARS-CoV-like coronaviruses², it is likely that bats serve as reservoir hosts for its progenitor. Although RaTG13, sampled from a Rhinolophus affinis bat¹, is ~96% identical overall to SARS-CoV-2, its spike diverges in the RBD, which suggests that it may not bind efficiently to human ACE2⁷ (Fig. 1a).

Malayan pangolins (Manis javanica) illegally imported into Guangdong province contain coronaviruses similar to SARS-CoV-2²¹. Although the RaTG13 bat virus remains the closest to SARS-CoV-2 across the genome¹, some pangolin coronaviruses exhibit strong similarity to SARS-CoV-2 in the RBD, including all six key RBD residues²¹ (Fig. 1). This clearly shows that the SARS-CoV-2 spike protein optimized for binding to human-like ACE2 is the result of natural selection.

Neither the bat betacoronaviruses nor the pangolin betacoronaviruses sampled thus far have polybasic cleavage sites. Although no animal coronavirus has been identified that is sufficiently similar to have served as the direct progenitor of SARS-CoV-2, the diversity of coronaviruses in bats and other species is massively undersampled. Mutations, insertions and deletions can occur near the S1–S2 junction of coronaviruses²², which shows that the polybasic cleavage site can arise by a natural evolutionary process. For a precursor virus to acquire both the polybasic cleavage site and mutations in the spike protein suitable for binding to human ACE2, an animal host would probably have to have a high population density (to allow natural selection to proceed efficiently) and an ACE2-encoding gene that is similar to the human ortholog.

2. Natural selection in humans following zoonotic transfer

It is possible that a progenitor of SARS-CoV-2 jumped into humans, acquiring the genomic features described above through adaptation during undetected human-to-human transmission. Once acquired, these adaptations would enable the pandemic to take off and produce a sufficiently large cluster of cases to trigger the surveillance system that detected it^1,2.

All SARS-CoV-2 genomes sequenced so far have the genomic features described above and are thus derived from a common ancestor that had them too. The presence in pangolins of an RBD very similar to that of SARS-CoV-2 means that we can infer this was also probably in the virus that jumped to humans. This leaves the insertion of polybasic cleavage site to occur during human-to-human transmission.

Estimates of the timing of the most recent common ancestor of SARS-CoV-2 made with current sequence data point to emergence of the virus in late November 2019 to early December 2019²³, compatible with the earliest retrospectively confirmed cases²⁴. Hence, this scenario presumes a period of unrecognized transmission in humans between the initial zoonotic event and the acquisition of the polybasic cleavage site. Sufficient opportunity could have arisen if there had been many prior zoonotic events that produced short chains of human-to-human transmission over an extended period. This is essentially the situation for MERS-CoV, for which all human cases are the result of repeated jumps of the virus from dromedary camels, producing single infections or short transmission chains that eventually resolve, with no adaptation to sustained transmission²⁵.

Studies of banked human samples could provide information on whether such cryptic spread has occurred. Retrospective serological studies could also be informative, and a few such studies have been conducted showing low-level exposures to SARS-CoV-like coronaviruses in certain areas of China²⁶. Critically, however, these studies could not have distinguished whether exposures were due to prior infections with SARS-CoV, SARS-CoV-2 or other SARS-CoV-like coronaviruses. Further serological studies should be conducted to determine the extent of prior human exposure to SARS-CoV-2.

3. Selection during passage

Basic research involving passage of bat SARS-CoV-like coronaviruses in cell culture and/or animal models has been ongoing for many years in biosafety level 2 laboratories across the world²⁷, and there are documented instances of laboratory escapes of SARS-CoV²⁸. We must therefore examine the possibility of an inadvertent laboratory release of SARS-CoV-2.

In theory, it is possible that SARS-CoV-2 acquired RBD mutations (Fig. 1a) during adaptation to passage in cell culture, as has been observed in studies of SARS-CoV¹¹. The finding of SARS-CoV-like coronaviruses from pangolins with nearly identical RBDs, however, provides a much stronger and more parsimonious explanation of how SARS-CoV-2 acquired these via recombination or mutation¹⁹.

The acquisition of both the polybasic cleavage site and predicted O-linked glycans also argues against culture-based scenarios. New polybasic cleavage sites have been observed only after prolonged passage of low-pathogenicity avian influenza virus in vitro or in vivo¹⁷. Furthermore, a hypothetical generation of SARS-CoV-2 by cell culture or animal passage would have required prior isolation of a progenitor virus with very high genetic similarity, which has not been described. Subsequent generation of a polybasic cleavage site would have then required repeated passage in cell culture or animals with ACE2 receptors similar to those of humans, but such work has also not previously been described. Finally, the generation of the predicted O-linked glycans is also unlikely to have occurred due to cell-culture passage, as such features suggest the involvement of an immune system¹⁸.

Conclusions

In the midst of the global COVID-19 public-health emergency, it is reasonable to wonder why the origins of the pandemic matter. Detailed understanding of how an animal virus jumped species boundaries to infect humans so productively will help in the prevention of future zoonotic events. For example, if SARS-CoV-2 pre-adapted in another animal species, then there is the risk of future re-emergence events. In contrast, if the adaptive process occurred in humans, then even if repeated zoonotic transfers occur, they are unlikely to take off without the same series of mutations. In addition, identifying the closest viral relatives of SARS-CoV-2 circulating in animals will greatly assist studies of viral function. Indeed, the availability of the RaTG13 bat sequence helped reveal key RBD mutations and the polybasic cleavage site.

The genomic features described here may explain in part the infectiousness and transmissibility of SARS-CoV-2 in humans. Although the evidence shows that SARS-CoV-2 is not a purposefully manipulated virus, it is currently impossible to prove or disprove the other theories of its origin described here. However, since we observed all notable SARS-CoV-2 features, including the optimized RBD and polybasic cleavage site, in related coronaviruses in nature, we do not believe that any type of laboratory-based scenario is plausible.

More scientific data could swing the balance of evidence to favor one hypothesis over another. Obtaining related viral sequences from animal sources would be the most definitive way of revealing viral origins. For example, a future observation of an intermediate or fully formed polybasic cleavage site in a SARS-CoV-2-like virus from animals would lend even further support to the natural-selection hypotheses. It would also be helpful to obtain more genetic and functional data about SARS-CoV-2, including animal studies. The identification of a potential intermediate host of SARS-CoV-2, as well as sequencing of the virus from very early cases, would similarly be highly informative. Irrespective of the exact mechanisms by which SARS-CoV-2 originated via natural selection, the ongoing surveillance of pneumonia in humans and other animals is clearly of utmost importance.

References

1.
Zhou, P. et al. Nature https://doi.org/10.1038/s41586-020-2012-7 (2020).

Article PubMed PubMed Central Google Scholar
2.
Wu, F. et al. Nature https://doi.org/10.1038/s41586-020-2008-3 (2020).

Article PubMed PubMed Central Google Scholar
3.
Gorbalenya, A. E. et al. bioRxiv https://doi.org/10.1101/2020.02.07.937862 (2020).

Article Google Scholar
4.
Jiang, S. et al. Lancet https://doi.org/10.1016/S0140-6736(20)30419-0 (2020).

Article PubMed PubMed Central Google Scholar
5.
Dong, E., Du, H. & Gardner, L. Lancet Infect. Dis. https://doi.org/10.1016/S1473-3099(20)30120-1 (2020).

Article PubMed Google Scholar
6.
Corman, V. M., Muth, D., Niemeyer, D. & Drosten, C. Adv. Virus Res. 100, 163–188 (2018).

Article Google Scholar
7.
Wan, Y., Shang, J., Graham, R., Baric, R. S. & Li, F. J. Virol. https://doi.org/10.1128/JVI.00127-20 (2020).

Article PubMed Google Scholar
8.
Walls, A. C. et al. bioRxiv https://doi.org/10.1101/2020.02.19.956581 (2020).

Article Google Scholar
9.
Wrapp, D. et al. Science https://doi.org/10.1126/science.abb2507 (2020).

Article PubMed Google Scholar
10.
Letko, M., Marzi, A. & Munster, V. Nat. Microbiol. https://doi.org/10.1038/s41564-020-0688-y (2020).

Article PubMed PubMed Central Google Scholar
11.
Sheahan, T. et al. J. Virol. 82, 2274–2285 (2008).

CAS Article Google Scholar
12.
Nao, N. et al. MBio 8, e02298-16 (2017).

Article Google Scholar
13.
Chan, C.-M. et al. Exp. Biol. Med. 233, 1527–1536 (2008).

CAS Article Google Scholar
14.
Follis, K. E., York, J. & Nunberg, J. H. Virology 350, 358–369 (2006).

CAS Article Google Scholar
15.
Menachery, V. D. et al. J. Virol. https://doi.org/10.1128/JVI.01774-19 (2019).

Article PubMed Google Scholar
16.
Alexander, D. J. & Brown, I. H. Rev. Sci. Tech. 28, 19–38 (2009).

CAS Article Google Scholar
17.
Ito, T. et al. J. Virol. 75, 4439–4443 (2001).

CAS Article Google Scholar
18.
Bagdonaite, I. & Wandall, H. H. Glycobiology 28, 443–467 (2018).

CAS Article Google Scholar
19.
Cui, J., Li, F. & Shi, Z.-L. Nat. Rev. Microbiol. 17, 181–192 (2019).

CAS Article Google Scholar
20.
Almazán, F. et al. Virus Res. 189, 262–270 (2014).

Article Google Scholar
21.
Zhang, T., Wu, Q. & Zhang, Z. bioRxiv https://doi.org/10.1101/2020.02.19.950253 (2020).

Article Google Scholar
22.
Yamada, Y. & Liu, D. X. J. Virol. 83, 8744–8758 (2009).

CAS Article Google Scholar
23.
Rambaut, A. Virological.org http://virological.org/t/356 (2020).
24.
Huang, C. et al. Lancet https://doi.org/10.1016/S0140-6736(20)30183-5 (2020).

Article PubMed PubMed Central Google Scholar
25.
Dudas, G., Carvalho, L. M., Rambaut, A. & Bedford, T. eLife 7, e31257 (2018).

Article Google Scholar
26.
Wang, N. et al. Virol. Sin. 33, 104–107 (2018).

Article Google Scholar
27.
Ge, X.-Y. et al. Nature 503, 535–538 (2013).

CAS Article Google Scholar
28.
Lim, P. L. et al. N. Engl. J. Med. 350, 1740–1745 (2004).

CAS Article Google Scholar
29.
Wong, M. C., Javornik Cregeen, S. J., Ajami, N. J. & Petrosino, J. F. bioRxiv https://doi.org/10.1101/2020.02.07.939207 (2020).

Article Google Scholar
30.
Liu, P., Chen, W. & Chen, J.-P. Viruses 11, 979 (2019).

CAS Article Google Scholar

Download references

Acknowledgements

We thank all those who have contributed sequences to the GISAID database (https://www.gisaid.org/) and analyses to Virological.org (http://virological.org/). We thank M. Farzan for discussions, and the Wellcome Trust for support. K.G.A. is a Pew Biomedical Scholar and is supported by NIH grant U19AI135995. A.R. is supported by the Wellcome Trust (Collaborators Award 206298/Z/17/Z―ARTIC network) and the European Research Council (grant agreement no. 725422―ReservoirDOCS). E.C.H. is supported by an ARC Australian Laureate Fellowship (FL170100022). R.F.G. is supported by NIH grants U19AI135995, U54 HG007480 and U19AI142790.

Author information

Affiliations

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA

Kristian G. Andersen
Scripps Research Translational Institute, La Jolla, CA, USA

Kristian G. Andersen
Institute of Evolutionary Biology, University of Edinburgh, Edinburgh, UK

Andrew Rambaut
Center for Infection and Immunity, Mailman School of Public Health of Columbia University, New York, NY, USA

W. Ian Lipkin
Marie Bashir Institute for Infectious Diseases and Biosecurity, School of Life and Environmental Sciences and School of Medical Sciences, The University of Sydney, Sydney, Australia

Edward C. Holmes
Tulane University, School of Medicine, Department of Microbiology and Immunology, New Orleans, LA, USA

Robert F. Garry
Zalgen Labs, Germantown, MD, USA

Robert F. Garry

Corresponding author

Correspondence to Kristian G. Andersen.

Ethics declarations

Competing interests

R.F.G. is co-founder of Zalgen Labs, a biotechnology company that develops countermeasures to emerging viruses.

Rights and permissions

Oct 19

Σάλος στις ΗΠΑ από τις αποκαλύψεις του σχεδίου “αλήθεια” project veritas.

By Γεώργιος Ευαγγελάτος in Επιστήμη

Τρεις γιατροί που εργάζονταν στην Pfizer, ο Chris Crose, ο Nick Karl και ο Rahul Khandke απεκάλυψαν σε κρυφή κάμερα (ποιο νόημα έχει η κρυφή αφού ανέφεραν και τα ονόματά τους, σίγουρα ήσαν υπό απόλυση) τα αίσχη και τις παρανομίες της Pfizer όσον αφορά τα εμβόλια. Κάτι που δεν μας ξενίζει καθώς η ίδια Εταιρεία έχει πληρώσει εκατομμύρια δολάρια πρόστιμο για πολυάριθμες παραβιάσεις και παρανομίες που έχει κάνει.

Αλλά δείτε το βίντεο:

Oct 19

57 Top Scientists And Doctors Release Shocking Study On COVID Vaccines and Demand Immediate Stop to ALL Vaccinations

By Γεώργιος Ευαγγελάτος in Επιστήμη, Μελέτη

57 Top Scientists And Doctors Release Shocking Study On COVID Vaccines

5 months ago 363.7k Views

A group of 57 leading scientists, doctors and policy experts has released a report calling in to question the safety and efficacy of the current COVID-19 vaccines and are now calling for an immediate end to all vaccine programs. We urge you to read and share this damning report.

There are two certainties regarding the global distribution of Covid-19 vaccines. The first is that governments and the vast majority of the mainstream media are pushing with all their might to get these experimental drugs into as many people as possible. The second is that those who are willing to face the scorn that comes with asking serious questions about vaccines are critical players in our ongoing effort to spread the truth.

You can read an advanced copy of this manuscript in preprint below. It has been prepared by nearly five dozen highly respected doctors, scientists, and public policy experts from across the globe to be urgently sent to world leaders as well as all who are associated with the production and distribution of the various Covid-19 vaccines in circulation today.

There are still far too many unanswered questions regarding the Covid-19 vaccines’ safety, efficacy, and necessity. This study is a bombshell that should be heard by everyone, regardless of their views on vaccines. There aren’t nearly enough citizens who are asking questions. Most people simply follow the orders of world governments, as if they have earned our complete trust. They haven’t done so. This manuscript is a step forward in terms of accountability and the free flow of information on this crucial subject. Please take the time to read it and share it widely.

SARS-CoV-2 mass vaccination: Urgent questions on vaccine safety that demand answers from international health agencies, regulatory authorities, governments and vaccine developers

Roxana Bruno¹, Peter McCullough², Teresa Forcades i Vila³, Alexandra Henrion-Caude⁴, Teresa García-Gasca⁵, Galina P. Zaitzeva⁶, Sally Priester⁷, María J. Martínez Albarracín⁸, Alejandro Sousa-Escandon⁹, Fernando López Mirones¹⁰, Bartomeu Payeras Cifre¹¹, Almudena Zaragoza Velilla¹⁰, Leopoldo M. Borini¹, Mario Mas¹, Ramiro Salazar¹, Edgardo Schinder¹, Eduardo A Yahbes¹, Marcela Witt¹, Mariana Salmeron¹, Patricia Fernández¹, Miriam M. Marchesini¹, Alberto J. Kajihara¹, Marisol V. de la Riva¹, Patricia J. Chimeno¹, Paola A. Grellet¹, Matelda Lisdero¹, Pamela Mas¹, Abelardo J. Gatica Baudo¹², Elisabeth Retamoza¹², Oscar Botta¹³, Chinda C. Brandolino¹³, Javier Sciuto¹⁴, Mario Cabrera Avivar¹⁴, Mauricio Castillo¹⁵, Patricio Villarroel¹⁵, Emilia P. Poblete Rojas¹⁵, Bárbara Aguayo¹⁵, Dan I. Macías Flores¹⁵, Jose V. Rossell¹⁶, Julio C. Sarmiento¹⁷, Victor Andrade-Sotomayor¹⁷, Wilfredo R. Stokes Baltazar¹⁸, Virna Cedeño Escobar¹⁹, Ulises Arrúa²⁰, Atilio Farina del Río²¹, Tatiana Campos Esquivel²², Patricia Callisperis²³, María Eugenia Barrientos²⁴, Karina Acevedo-Whitehouse⁵,*

¹Epidemiólogos Argentinos Metadisciplinarios. República Argentina.
²Baylor University Medical Center. Dallas, Texas, USA.
³Monestir de Sant Benet de Montserrat, Montserrat, Spain
⁴INSERM U781 Hôpital Necker-Enfants Malades, Université Paris Descartes-Sorbonne Cité, Institut Imagine, Paris, France.
⁵School of Natural Sciences. Autonomous University of Querétaro, Querétaro, Mexico.
⁶Retired Professor of Medical Immunology. Universidad de Guadalajara, Jalisco, Mexico.
⁷Médicos por la Verdad Puerto Rico. Ashford Medical Center. San Juan, Puerto Rico.
⁸Retired Professor of Clinical Diagnostic Processes. University of Murcia, Murcia, Spain
⁹Urologist Hospital Comarcal de Monforte, University of Santiago de Compostela, Spain.
¹⁰Biólogos por la Verdad, Spain.
¹¹Retired Biologist. University of Barcelona. Specialized in Microbiology. Barcelona, Spain.
¹²Center for Integrative Medicine MICAEL (Medicina Integrativa Centro Antroposófico Educando en Libertad). Mendoza, República Argentina.
¹³Médicos por la Verdad Argentina. República Argentina. ´
¹⁴Médicos por la Verdad Uruguay. República Oriental del Uruguay.
¹⁵Médicos por la Libertad Chile. República de Chile.
¹⁶Physician, orthopedic specialist. República de Chile.
¹⁷Médicos por la Verdad Perú. República del Perú.
¹⁸Médicos por la Verdad Guatemala. República de Guatemala.
¹⁹Concepto Azul S.A. Ecuador.
²⁰Médicos por la Verdad Brasil. Brasil.
²¹Médicos por la Verdad Paraguay.
²²Médicos por la Costa Rica.
²³Médicos por la Verdad Bolivia.
²⁴Médicos por la Verdad El Salvador.
* Correspondence: Karina Acevedo-Whitehouse, karina.acevedo.whitehouse@uaq.mx

Abstract

Since the start of the COVID-19 outbreak, the race for testing new platforms designed to confer immunity against SARS-CoV-2, has been rampant and unprecedented, leading to emergency authorization of various vaccines. Despite progress on early multidrug therapy for COVID-19 patients, the current mandate is to immunize the world population as quickly as possible. The lack of thorough testing in animals prior to clinical trials, and authorization based on safety data generated during trials that lasted less than 3.5 months, raise questions regarding the safety of these vaccines. The recently identified role of SARS-CoV-2 glycoprotein Spike for inducing endothelial damage characteristic of COVID-19, even in absence of infection, is extremely relevant given that most of the authorized vaccines induce the production of Spike glycoprotein in the recipients. Given the high rate of occurrence of adverse effects, and the wide range of types of adverse effects that have been reported to date, as well as the potential for vaccine-driven disease enhancement, Th2-immunopathology, autoimmunity, and immune evasion, there is a need for a better understanding of the benefits and risks of mass vaccination, particularly in the groups that were excluded in the clinical trials. Despite calls for caution, the risks of SARS-CoV-2 vaccination have been minimized or ignored by health organizations and government authorities. We appeal to the need for a pluralistic dialogue in the context of health policies, emphasizing critical questions that require urgent answers if we wish to avoid a global erosion of public confidence in science and public health.

Introduction

Since COVID-19 was declared a pandemic in March 2020, over 150 million cases and 3 million deaths have been reported worldwide. Despite progress on early ambulatory, multidrug-therapy for high-risk patients, resulting in 85% reductions in COVID-19 hospitalization and death [1], the current paradigm for control is mass-vaccination. While we recognize the effort involved in development, production and emergency authorization of SARS-CoV-2 vaccines, we are concerned that risks have been minimized or ignored by health organizations and government authorities, despite calls for caution [2-8].

Vaccines for other coronaviruses have never been approved for humans, and data generated in the development of coronavirus vaccines designed to elicit neutralizing antibodies show that they may worsen COVID-19 disease via antibody-dependent enhancement (ADE) and Th2 immunopathology, regardless of the vaccine platform and delivery method [9-11]. Vaccine-driven disease enhancement in animals vaccinated against SARS-CoV and MERS-CoV is known to occur following viral challenge, and has been attributed to immune complexes and Fc-mediated viral capture by macrophages, which augment T-cell activation and inflammation [11-13].

In March 2020, vaccine immunologists and coronavirus experts assessed SARS-CoV-2 vaccine risks based on SARS-CoV-vaccine trials in animal models. The expert group concluded that ADE and immunopathology were a real concern, but stated that their risk was insufficient to delay clinical trials, although continued monitoring would be necessary [14]. While there is no clear evidence of the occurrence of ADE and vaccine-related immunopathology in volunteers immunized with SARS-CoV-2 vaccines [15], safety trials to date have not specifically addressed these serious adverse effects (SAE). Given that the follow-up of volunteers did not exceed 2-3.5 months after the second dose [16-19], it is unlikely such SAE would have been observed. Despite92 errors in reporting, it cannot be ignored that even accounting for the number of vaccines administered, according to the US Vaccine Adverse Effect Reporting System (VAERS), the number of deaths per million vaccine doses administered has increased more than 10-fold. We believe there is an urgent need for open scientific dialogue on vaccine safety in the context of large-scale immunization. In this paper, we describe some of the risks of mass vaccination in the context of phase 3 trial exclusion criteria and discuss the SAE reported in national and regional adverse effect registration systems. We highlight unanswered questions and draw attention to the need for a more cautious approach to mass vaccination.

SARS-CoV-2 phase 3 trial exclusion criteria

With few exceptions, SARS-CoV-2 vaccine trials excluded the elderly [16-19], making it impossible to identify the occurrence of post-vaccination eosinophilia and enhanced inflammation in elderly people. Studies of SARS-CoV vaccines showed that immunized elderly mice were at particularly high risk of life-threatening Th2 immunopathology [9,20]. Despite this evidence and the extremely limited data on safety and efficacy of SARS-CoV-2 vaccines in the elderly, mass-vaccination campaigns have focused on this age group from the start. Most trials also excluded pregnant and lactating volunteers, as well as those with chronic and serious conditions such as tuberculosis, hepatitis C, autoimmunity, coagulopathies, cancer, and immune suppression [16-29], although these recipients are now being offered the vaccine under the premise of safety.

Another criterion for exclusion from nearly all trials was prior exposure to SARS-CoV-2. This is unfortunate as it denied the opportunity of obtaining extremely relevant information concerning post-vaccination ADE in people that already have anti-SARS-Cov-2 antibodies. To the best of our knowledge, ADE is not being monitored systematically for any age or medical condition group currently being administered the vaccine. Moreover, despite a substantial proportion of the population already having antibodies [21], tests to determine SARS-CoV-2-antibody status prior to administration of the vaccine are not conducted routinely.

Will serious adverse effects from the SARS-CoV-2 vaccines go unnoticed?

COVID-19 encompasses a wide clinical spectrum, ranging from very mild to severe pulmonary pathology and fatal multi-organ disease with inflammatory, cardiovascular, and blood coagulation dysregulation [22-24]. In this sense, cases of vaccine-related ADE or immunopathology would be clinically-indistinguishable from severe COVID-19 [25]. Furthermore, even in the absence of SARS-CoV-2 virus, Spike glycoprotein alone causes endothelial damage and hypertension in vitro and in vivo in Syrian hamsters by down-regulating angiotensin-converting enzyme 2 (ACE2) and impairing mitochondrial function [26]. Although these findings need to be confirmed in humans, the implications of this finding are staggering, as all vaccines authorized for emergency use are based on the delivery or induction of Spike glycoprotein synthesis. In the case of mRNA vaccines and adenovirus-vectorized vaccines, not a single study has examined the duration of Spike production in humans following vaccination. Under the cautionary principle, it is parsimonious to consider vaccine-induced Spike synthesis could cause clinical signs of severe COVID-19, and erroneously be counted as new cases of SARS-CoV-2 infections. If so, the true adverse effects of the current global vaccination strategy may never be recognized unless studies specifically examine this question. There is already non-causal evidence of temporary or sustained increases138 in COVID-19 deaths following vaccination in some countries (Fig. 1) and in light of Spike’s pathogenicity, these deaths must be studied in depth to determine whether they are related to vaccination.

Unanticipated adverse reactions to SARS-CoV-2 vaccines

Another critical issue to consider given the global scale of SARS-CoV-2 vaccination is autoimmunity. SARS-CoV-2 has numerous immunogenic proteins, and all but one of its immunogenic epitopes have similarities to human proteins [27]. These may act as a source of antigens, leading to autoimmunity [28]. While it is true that the same effects could be observed during natural infection with SARS-CoV-2, vaccination is intended for most of the world population, while it is estimated that only 10% of the world population has been infected by SARS-CoV-2, according to Dr. Michael Ryan, head of emergencies at the World Health Organization. We have been unable to find evidence that any of the currently authorized vaccines screened and excluded homologous immunogenic epitopes to avoid potential autoimmunity due to pathogenic priming.

Some adverse reactions, including blood-clotting disorders, have already been reported in healthy and young vaccinated people. These cases led to the suspension or cancellation of the use of adenoviral vectorized ChAdOx1-nCov-19 and Janssen vaccinesin some countries. It has now been proposed that vaccination with ChAdOx1-nCov-19 can result in immune thrombotic thrombocytopenia (VITT) mediated by platelet-activating antibodies against Platelet factor-4, which clinically mimics autoimmune heparin-induced thrombocytopenia [29]. Unfortunately, the risk was overlooked when authorizing these vaccines, although adenovirus-induced thrombocytopenia has been known for more than a decade, and has been a consistent event with adenoviral vectors [30]. The risk of VITT would presumably be higher in those already at risk of blood clots, including women who use oral contraceptives [31], making it imperative for clinicians to advise their patients accordingly.

At the population level, there could also be vaccine-related impacts. SARS-CoV-2 is a fast-evolving RNA virus that has so far produced more than 40,000 variants [32,33] some of which affect the antigenic domain of Spike glycoprotein [34,35]. Given the high mutation rates, vaccine-induced synthesis of high levels of anti-SARS-CoV-2-Spike antibodies could theoretically lead to suboptimal responses against subsequent infections by other variants in vaccinated individuals [36], a phenomenon known as “original antigenic sin” [37] or antigenic priming [38]. It is unknown to what extent mutations that affect SARS-CoV-2 antigenicity will become fixed during viral evolution [39], but vaccines could plausibly act as selective forces driving variants with higher infectivity or transmissibility. Considering the high similarity between known SARS-CoV-2 variants, this scenario is unlikely [32,34] but if future variants were to differ more in key epitopes, the global vaccination strategy might have helped shape an even more dangerous virus. This risk has recently been brought to the attention of the WHO as an open letter [40].

Discussion

The risks outlined here are a major obstacle to continuing global SARS-CoV-2 vaccination. Evidence on the safety of all SARS-CoV-2 vaccines is needed before exposing more people to the184 risk of these experiments, since releasing a candidate vaccine without time to fully understand the resulting impact on health could lead to an exacerbation of the current global crisis [41]. Risk-stratification of vaccine recipients is essential. According to the UK government, people below 60 years of age have an extremely low risk of dying from COVID-191 187 . However, according to Eudravigillance, most of the serious adverse effects following SARS-CoV-2 vaccination occur in people aged 18-64. Of particular concern is the planned vaccination schedule for children aged 6 years and older in the United States and the UK. Dr. Anthony Fauci recently anticipated that teenagers across the country will be vaccinated in the autumn and younger children in early 2022, and the UK is awaiting trial results to commence vaccination of 11 million children under 18. There is a lack of scientific justification for subjecting healthy children to experimental vaccines, given that the Centers for Disease Control and Prevention estimates that they have a 99.997% survival rate if infected with SARS-CoV-2. Not only is COVID-19 irrelevant as a threat to this age group, but there is no reliable evidence to support vaccine efficacy or effectiveness in this population or to rule out harmful side effects of these experimental vaccines. In this sense, when physicians advise patients on the elective administration of COVID-19 vaccination, there is a great need to better understand the benefits and risk of administration, particularly in understudied groups.

In conclusion, in the context of the rushed emergency-use-authorization of SARS-CoV-2 vaccines, and the current gaps in our understanding of their safety, the following questions must be raised:

Is it known whether cross-reactive antibodies from previous coronavirus infections or vaccine206 induced antibodies may influence the risk of unintended pathogenesis following vaccination with COVID-19?
Has the specific risk of ADE, immunopathology, autoimmunity, and serious adverse reactions been clearly disclosed to vaccine recipients to meet the medical ethics standard of patient understanding for informed consent? If not, what are the reasons, and how could it be implemented?
What is the rationale for administering the vaccine to every individual when the risk of dying from COVID-19 is not equal across age groups and clinical conditions and when the phase 3 trials excluded the elderly, children and frequent specific conditions?
What are the legal rights of patients if they are harmed by a SARS-CoV-2 vaccine? Who will cover the costs of medical treatment? If claims were to be settled with public money, has the public been made aware that the vaccine manufacturers have been granted immunity, and their responsibility to compensate those harmed by the vaccine has been transferred to the tax-payers?

In the context of these concerns, we propose halting mass-vaccination and opening an urgent pluralistic, critical, and scientifically-based dialogue on SARS-CoV-2 vaccination among scientists, medical doctors, international health agencies, regulatory authorities, governments, and vaccine developers. This is the only way to bridge the current gap between scientific evidence and public health policy regarding the SARS-CoV-2 vaccines. We are convinced that humanity deserves a deeper understanding of the risks than what is currently touted as the official position. An open scientific dialogue is urgent and indispensable to avoid erosion of public confidence in science and public health and to ensure that the WHO and national health authorities protect the interests of humanity during the current pandemic. Returning public health policy to evidence-based medicine, relying on a careful evaluation of the relevant scientific research, is urgent. It is imperative to follow the science.

1 https://www.gov.uk/government/publications/covid-19-reported-sars-cov-2-deaths-in-england/covid-19-confirmed-deaths-in-england-report

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

McCullough PA, Alexander PE, Armstrong R, et al. Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19). Rev Cardiovasc Med (2020) 21:517–530. doi:10.31083/j.rcm.2020.04.264
Arvin AM, Fink K, Schmid MA, et al. A perspective on potential antibody- dependent enhancement of SARS-CoV-2. Nature (2020) 484:353–363. doi:10.1038/s41586-020-2538-8
Coish JM, MacNeil AJ. Out of the frying pan and into the fire? Due diligence warranted for ADE in COVID-19. Microbes Infect (2020) 22(9):405-406. doi:10.1016/j.micinf.2020.06.006
Eroshenko N, Gill T, Keaveney ML, et al. Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures. Nature Biotechnol (2020) 38:788–797. doi:10.1038/s41587-020-0577-1
Poland GA. Tortoises, hares, and vaccines: A cautionary note for SARS-CoV-2 vaccine development. Vaccine (2020) 38:4219–4220. doi:10.1016/j.vaccine.2020.04.073
Shibo J. Don’t rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees. Nature (2000) 579,321. doi:10.1038/d41586-020-00751-9
Munoz FA, Cramer JP, Dekker CL, et al. Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine (2021) https://doi.org/10.1016/j.vaccine.2021.01.055
Cardozo T, Veazey R. Informed consent disclosure to vaccine trial subjects of risk of COVID-19 vaccines worsening clinical disease. Int J Clin Pract (2020) 28:e13795. doi: 10.1111/ijcp.13795
Bolles D, Long K, Adnihothram S, et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J Virol (2001) 85:12201–12215. doi:10.1128/JVI.06048-11
Weingartl H, Czub M, Czub S, et al. Immunization with modified vaccinia virus Ankarabased recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol (2004) 78:12672–12676. doi:10.1128/JVI.78.22.12672-12676.2004272
Tseng CT, Sbrana E, Iwata-Yoshikawa N, et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One (2012) 7(4):e35421. doi: 10.1371/journal.pone.0035421
Iwasaki A, Yang Y. The potential danger of suboptimal antibody responses in COVID-19. Nat Rev Immunol (2020) 20:339–341. doi:10.1038/s41577-020-0321-6
Vennema H, de Groot RJ, Harbour DA, et al. Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization. J Virol (1990) 64:1407-1409
Lambert PH, Ambrosino DM, Andersen SR, et al. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines. Vaccine (2020) 38(31):4783-4791. doi:10.1016/j.vaccine.2020.05.064
de Alwis R, Chen S, Gan S, et al. Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development. EbioMedicine (2020) 55:102768. doi:10.1016/j.ebiom.2020.102768
Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV287 19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet (2020) 396:467–783. doi:10.1016/S0140-6736(20)31604-4
Polack FP, Thomas SJ, Kitchin N. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med (2020) 383:2603–2615. doi:10.1056/NEJMoa2034577
Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet (2021) 396:1979–93. doi: 10.1016/S0140-6736(20)32466-1
Chu L, McPhee R, Huang W, et al. mRNA-1273 Study Group. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine (2021) S0264-410X(21)00153-5. doi:10.1016/j.vaccine.2021.02.007
Liu L, Wei Q, Lin Q, et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight (2019) 4(4):e123158. doi:10.1172/jci.insight.123158.
Ioannidis PA. Infection fatality rate of COVID-19 inferred from seroprevalence data. Bull WHO (2021) 99:19–33F. http://dx.doi.org/10.2471/BLT.20.265892
Martines RB, Ritter JM, Matkovic E, et al. Pathology and Pathogenesis of SARS-CoV-2 Associated with Fatal Coronavirus Disease, United States Emerg Infect Dis (2020) 26:2005-2015. doi:10.3201/eid2609.202095
Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA (2020) 323:1239-1242. doi:10.1001/jama.2020.2648
Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respiratory Med (2020) 8:420-422 doi:10.1016/S2213-2600(20)30076-X
Negro F. Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis? Swiss Medical Weekly (2020) 150:w20249. doi:10.4414/smw.2020.20249317
Lei Y, Zhang J, Schiavon CR et al., Spike Protein Impairs Endothelial Function via Downregulation of ACE 2. Circulation Res (2021) 128:1323–1326. https://doi.org/10.1161/CIRCRESAHA.121.318902
Lyons-Weiler J. Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity, J Translational Autoimmunity (2020) 3:100051. doi:10.1016/j.jtauto.2020.100051
An H, Park J. Molecular Mimicry Map (3M) of SARS-CoV-2: Prediction of potentially immunopathogenic SARS-CoV-2 epitopes via a novel immunoinformatic approach. bioRxiv [Preprint]. 12 November 2020 [cited 2020 April 19] https://doi.org/10.1101/2020.11.12.344424
Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med (2021). doi: 10.1056/NEJMoa2104840
Othman M, Labelle A, Mazzetti I et al. Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance. Blood (2007) 109:2832–2839. doi:10.1182/blood-2006-06-032524
Ortel TL. Acquired thrombotic risk factors in the critical care setting. Crit Care Med (2010) 38(2 Suppl):S43-50. doi:10.1097/CCM.0b013e3181c9ccc8
Grubaugh ND, Petrone ME, Holmes EC. We shouldn’t worry when a virus mutates during disease outbreaks. Nat Microbiol (2020) 5:529–530. https://doi.org/10.1038/s41564-020-0690-4
Greaney AJ, Starr TN, Gilchuk P, et al. Complete Mapping of Mutations to the SARS-CoV339 2 Spike Receptor-Binding Domain that Escape Antibody Recognition. Cell Host Microbe (2021) 29:44–57.e9. doi:10.1016/j.chom.2020.11.007.
Lauring AS, Hodcroft EB. Genetic Variants of SARS-CoV-2—What Do They Mean? JAMA (2021) 325:529–531. doi:10.1001/jama.2020.27124
Zhang L, Jackson CB, Mou H, et al. The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. bioRxiv [Preprint]. June 12 2020 [cited 2021 Apr 19] https://doi.org/10.1101/2020.06.12.148726
Korber B, Fischer WM, Gnanakaran S et al. Sheffield COVID-19 Genomics Group. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell (2020) 182:812-827.e19. doi:10.1016/j.cell.2020.06.043
Francis T. On the doctrine of original antigenic sin. Proc Am Philos Soc (1960) 104:572–578.
Vibroud C, Epstein SL. First flu is forever. Science (2016) 354:706–707. doi:10.1126/science.aak9816
Weisblum Y, Schmidt F, Zhang F, et al. Escape from neutralizing antibodies by SARS354 CoV-2 spike protein variants. Elife (2020) 9:e61312. doi:10.7554/eLife.61312
Vanden Bossche G (March 6, 2021) https://dryburgh.com/wp-356content/uploads/2021/03/Geert_Vanden_Bossche_Open_Letter_WHO_March_6_2021.pdf
Coish JM, MacNeil AJ. Out of the frying pan and into the fire? Due diligence warranted for ADE in COVID-19. Microbes Infect (2020) 22(9):405-406. doi:10.1016/j.micinf.2020.06.006

Figure legends

Figure 1. Number of new COVID-19 deaths in relation to number of people that have received at least one vaccine dose for selected countries. Graph shows data from the start of vaccination to May 3rd 365 , 2021. A) India (9.25% of population vaccinated), B) Thailand (1.58% of population vaccinated), C) Colombia (6.79% of population vaccinated), D) Mongolia (31.65% of population vaccinated), E) Israel (62.47% of population vaccinated), F) Entire world (7.81% of population vaccinated). Graphs were built using data from Our World in Data (accessed 4 May 2021) https://github.com/owid/covid-19-data/tree/master/public/data/vaccinations

COVID Vaccine COVID Vaccine Death COVID Vaccine Reaction vaccines

Source:https://en-volve.com/2021/05/08/57-top-scientists-and-doctors-release-shocking-study-on-covid-vaccines-and-demand-immediate-stop-to-all-vaccinations/

Leave comment

Oct 19

Ένας κορυφαίος γιατρός ο Dr. McCullough μιλά για ανθρωπιστική καταστροφή από τα εμβόλια για τον Κορωνοιό

By Γεώργιος Ευαγγελάτος in Απόδοση Δικαιοσύνης, Γενική Εξέγερση

Δίκτυο Ελληνισμού

Published October 15, 2021

COVID Vaccine Biggest Biological Catastrophe With Medicinal Product In Human History – Dr. McCullough

Red Voice Media said infront of

Τι συνέβη? Λοιπόν, γνωρίζουμε τώρα ότι αυτή η έγκαιρη προειδοποίηση ασφάλειας σε αυτήν τη δημοσίευση αξιολόγησης από ομοτίμους συναδέλφους της Jessica Rose απέτυχε σαφώς. Κοιτάξτε πόσο υψηλοί ήταν οι αριθμοί θνησιμότητας μέχρι τον Απρίλιο. Σαφώς απέτυχε. Είχαμε Αμερικανούς να πεθαίνουν μετά τον εμβολιασμό. Αυτό ήταν προφανές. Αυτό είναι ένα προφανές προειδοποιητικό σήμα δεδομένων. Όλοι οι ειδικοί συμφωνούν ότι είναι προφανές. Τώρα, από τις 24 Σεπτεμβρίου, έχουν ανέλθει σε συχνότητα θανάτων έως και 15.937 Αμερικανοί έχουν πεθάνει. Πάνω από 250.000 Αμερικανοί, μετά το εμβόλιο, νοσηλεύτηκαν, πήγαν σε επείγουσα περίθαλψη ή επισκέψεις στο γραφείο. Μπορείτε να δείτε τη χρονική σχέση στο γράφημα εδώ κάτω

Y.ou can see that sharp spike upwards. Sadly, we have over 20,000 Americans that the CDC tells us are permanently disabled after the vaccine. That’s bigger than some major Cancer groups. That’s bigger than some major Cancer groups. The disability that we are going to see due to these vaccines will go down in history as an unbelievable atrocity. I made a presentation to The Heritage Foundation in Washington that provides a lot of oversight to the House and the Senate, as well as the agencies, and I made this presentation.

Μπορείτε να δείτε αυτήν την απότομη κορυφή προς τα πάνω. Δυστυχώς, έχουμε πάνω από 20.000 Αμερικανούς για τους οποίους το CDC μας λέει ότι είναι μόνιμα ανάπηροι μετά το εμβόλιο. Αυτό το ποσοστό είναι μεγαλύτερο από μερικές μεγάλες ομάδες καρκίνου. Η αναπηρία που πρόκειται να δούμε λόγω αυτών των εμβολίων θα μείνει στην ιστορία ως μια απίστευτη θηριωδία. Έκανα μια παρουσίαση στο The Heritage Foundation στην Ουάσινγκτον που παρέχει μεγάλη ενημέρωση στο Σώμα των Αντιπροσώπων  και στη Γερουσία, καθώς και τους σχετικούς οργανισμούς, και έκανα αυτήν την παρουσίαση.

You could hear a pin drop when I was done, pin drop. And finally, one of the former presidents of the American Medical Association said, Dr. McCullough, we have the biggest biological catastrophe on our hands in human history with a medicinal product, and we’ve had two administrations buy into it. We’ve had all the houses of legislation buy into it. We have the entire medical established buy into it and the whole media and no one knows how to stop it. No one knows how to stop this freight train, and we’re all witnessing it right now.” –

Θα μπορούσατε να ακούσετε ως και μια πτώση καρφίτσας από την απόλυτη ησυχία που επικρτούσε όταν τελείωσα. Και τέλος, ένας από τους πρώην προέδρους της Αμερικανικής Ιατρικής Εταιρείας είπε:  Δρ ΜακΚάλοου, έχουμε τη μεγαλύτερη βιολογική καταστροφή στην ανθρώπινη ιστορία με ένα φαρμακευτικό προϊόν και είχαμε δύο Κυβερνήσεις του Τραμπ  και του Μπάϊντεν να το αγοράσουν.

Είχαμε εξαγοράσει όλα τα νομοθετικά κέντρα. Έχουμε εξαγοράσει ολόκληρο το ιατρικό κατεστημένο και όλα τα μέσα ενημέρωσης και κανείς δεν ξέρει πώς να το σταματήσει. Κανείς δεν ξέρει πώς να σταματήσει αυτό το φορτηγό τρένο και όλοι το παρακολουθούμε αυτή τη στιγμή να συνεχίζει το δρόμο προς την καταστροφή».

Dr. Peter McCullough

ΠΗΓΗ:https://thetruedefender.com/dr-mccullough-with-breaking-announcement-c-19-vaccine-the-biggest-biological-catastrophe/

Dr. McCullough With Breaking Announcement: C-19 Vaccine- The Biggest Biological Catastrophe!

WARNING!

Addison Wilson1 week ago

0 3 minutes read

The science that can’t be questioned is PROPAGANDA! Επιστήμη που δεν θέτει ερωτήματα είναι προπαγάνδα.

The real science and data prove that something’s not right with the official stories shared by the corrupted MSM. Η πραγματική επιστήμη και τα ορθά δεδομένα αποδεικνύουν ότι κάτι δεν είναι σωστό και οι επίσημες ιστορίες (πληροφορίες) διαδίδονται από διεφθαρμένα MSM.

They constantly share the phrases like ‘’Pandemic of the Unvaccinated,’’ ‘’Follow The Science,’’ ‘’Trust The Science.’’ Αυτοί συνεχώς χρησιμοποιούν φράσεις όπως “Η Πανδημία οφείλεται στους ανεμβολίαστους”,
“Ακολουθείστε τι λέει η επιστημη”, “εμπιστευτείτε την επιστήμη”.

Join The True Defender Telegram Chanel Here: https://t.me/TheTrueDefender

However, they very rarely present us the growing number of scientists, experts, doctors, healthcare workers’ information about the pandemic! Why? I guess it is because their statements don’t fit the officials’ narration.Εν τούτοις πολύ σπάνια μας παρουσιάζουν τον ολοένα αυξανόμενο αριθμό επιστημόνων, ειδικών, ιατρών, νοσηλευτών, που πληροφορούν περί της πανδημίας! Γιατί; Πιστεύω διότι οι δηλώσεις που κάνουν δεν συμφωνούν με τους πολιτικούς και την επίσημη άποψη.

If the MSM shares the actual truth, Big Pharma will lose billions! Αν τα Μέσα Μαζικής Επικοινωνίας μεταδώσουν την πραγματική αλήθεια η Big Pharma θα χάσει δισεκατομμύρια κέρδη..

Dr. Peter McCullough is but one of those Big Pharma people collaborating with Big Media and Big Tech trying to silence and censor. Ο ιατρός Peter McCullough είναιν ένας από εκείνους που οι 4 μεγάλες φαρμακευτικές Εταιρείες και όσοι συνεργάζονται με αυτές με τα μεγάλα Μέσα Ενημέρωσης και τις μεγάλες τεχνικές υπηρεσίες κάνουν τα αδύνατα δυνατά για να τους φιμώσουν και λογοκρίνουν.

Δείτε το βίντεο πιο κάτω την μετάφραση την διαβάσατε ήδη πιο πάνω:

What happened? Well, we now know that this early safety warning in this peer-review publication from Jessica Rose clearly failed. Look how high those mortality numbers were by April. It clearly failed. We had Americans dying after vaccination. It was obvious. This is an obvious data signal. This is obvious. All experts agree it’s obvious. Now, as of September 24th, it’s raced up to 15,937 Americans have died. Over 250,000 Americans, after the vaccine, have been hospitalized, gone to the urgent care or office visits. You can see the temporal relationship on the bottom bar graph. You can see that sharp spike upwards. Sadly, we have over 20,000 Americans that the CDC tells us are permanently disabled after the vaccine. That’s bigger than some major Cancer groups. That’s bigger than some major Cancer groups. The disability that we are going to see due to these vaccines will go down in history as an unbelievable atrocity. I made a presentation to The Heritage Foundation in Washington that provides a lot of oversight to the House and the Senate, as well as the agencies, and I made this presentation. You could hear a pin drop when I was done, pin drop. And finally, one of the former presidents of the American Medical Association said, Dr. McCullough, we have the biggest biological catastrophe on our hands in human history with a medicinal product, and we’ve had two administrations buy into it. We’ve had all the houses of legislation buy into it. We have the entire medical established buy into it and the whole media and no one knows how to stop it. No one knows how to stop this freight train, and we’re all witnessing it right now.” – Dr. Peter McCullough

I think every person has the reasonability to amplify the credible voices that have been silenced and stop them from informing you about the absolute truth!

Dr. McCullough is one of those persons.

Rumble — Ο Δρ McCullough έχει δημοσιεύσει ευρέως σε διάφορα ιατρικά θέματα με πάνω από 1000 δημοσιεύσεις και πάνω από 600 αναφορές στην Εθνική Βιβλιοθήκη Ιατρικής. Στις εργασίες του περιλαμβάνεται το κεφάλαιο “Σύνδεση μεταξύ νεφροπάθειας και καρδιοπάθειας” στο Εγχειρίδιο Καρδιοπάθειας του Braunwald. Ο Δρ McCullough είναι ιδρυτής και σημερινός πρόεδρος της Αμερικανικής Καρδιονεφρικής Εταιρείας, μιας οργάνωσης που έχει ως στόχο να φέρει σε επαφή καρδιολόγους και νεφρολόγους για να εργαστούν πάνω στο αναδυόμενο πρόβλημα των καρδιονεφρικών συνδρόμων. Έργα του έχουν δημοσιευθεί στο New England Journal of Medicine, στο Περιοδικό της Αμερικανικής Ιατρικής Ένωσης, στο Lancet, στο British Medical Journal και σε άλλα κορυφαία περιοδικά παγκοσμίως. Είναι αρχισυντάκτης του περιοδικού Ανασκοπήσεις στην Καρδιαγγειακή Ιατρική (Reviews in Cardiovascular Medicine) και ανώτερος συνεργάτης του Αμερικανικού Περιοδικού Καρδιολογίας. Είναι μέλος των συντακτικών επιτροπών πολλών ιατρικών περιοδικών. Ο Dr. McCullough έχει κάνει παρουσιάσεις σχετικά με την βελτίωση της ιατρικής σε όλο τον κόσμο και έχει υπάρξει προσκεκλημένος ομιλητής στην Ακαδημία Επιστημών της Νέας Υόρκης, στα Εθνικά Ινστιτούτα Υγείας, στον Οργανισμό Τροφίμων και Φαρμάκων των ΗΠΑ (FDA) και στον Ευρωπαϊκό Οργανισμό Φαρμάκων. Έχει διατελέσει μέλος ή πρόεδρος των επιτροπών παρακολούθησης της ασφάλειας δεδομένων σε 24 τυχαιοποιημένες κλινικές έρευνες.
(πηγή βιογραφικού:

https://www.heartplace.com/dr-peter-a-mccullough

Αυτό το βίντεο που σας μεταφράσαμε verbatum είναι από πρόσφατες δηλώσεις του για τα εμβόλια του κορωνοϊού (12 Οκτωβρίου 2021).
Σχετικά δημοσιεύματα στα αγγλικά:
α) Dr. McCullough With Breaking Announcement: C-19 Vaccine- The Biggest Biological Catastrophe!
β) 57 Top Scientists and Doctors: Stop All Covid Vaccinations

Oct 18

«Μας είχαν προειδοποιήσει οι ιατρικές αυθεντίες αλλά εμείς οι γιατροί και οι πολιτικοί τους αγνοήσαμε»

By Γεώργιος Ευαγγελάτος in Γενική Εξέγερση, Επιστήμη

Dr.P.McCullough: «Παίξαμε με την μητέρα φύση – Οι κυβερνήσεις πίεσαν για μαζικό εμβολιασμό και “αχρήστεψαν” τα εμβόλια»

«Μας είχαν προειδοποιήσει: Μην εμβολιάζεστε εν μέσω πανδημίας!»

Ο Dr. Peter A McCullough σύμβουλος Καρδιολόγος και Προϊστάμενος του Τμήματος Διατροφής και Προληπτικής Ιατρικής στο Νοσοκομείο William Beaumont στο Royal Oak, του Μίσιγκαν στις ΗΠΑ υποστήριξε ότι με τον μαζικό εμβολιασμό οι κυβερνήσεις «αχρήστευσαν» τα εμβόλια, καθώς ο ιός βρήκε τρόπο να ξεφύγει.

Ο γιατρός αναφέρθηκε σε συνέντευξη του στις δηλώσεις που είχαν κάνει επιστήμονες τους προηγούμενους μήνες και έλεγαν ότι δεν πρέπει να γίνουν μαζικοί εμβολιασμοί εν μέσω πανδημίας.

Όπως τόνισε στις δηλώσεις του ο λόγος που δημιουργήθηκε η μετάλλαξη Δέλτα, αλλά και άλλες μεταλλάξεις που καθιστούν άχρηστα τα υπάρχοντα εμβόλια είναι ακριβώς αυτός.

Ο γιατρός έδειξε τα στοιχεία του CDC για τα κρούσματα και θανάτους με Δέλτα σε εμβολιασμένους και μη και τόνισε τα εξής:

«Με το να ωθούν για μαζικούς εμβολιασμούς, οι κυβερνήσεις έχουν δημιουργήσει εξελικτικές πιέσεις στον SARS-coV-2. Και κάποιοι μάς προειδοποίησαν γι’ αυτό….

Ο Geert Vanden Bossche, ο Michael Yeadon, ο Sucharit Bhakdi, ο dr Luc Montagnier μας προειδοποίησαν γι’ αυτό. Μην εμβολιάζετε εν μέσω πανδημίας!

Είπαν ότι ο ιός θα ανακαλύψει αυτά τα εμβόλια και θα βρει τρόπο (να ξεφύγει). Η παραλλαγή Δέλτα είναι ακριβώς αυτό…. Έχει επιτύχει αντιγονική διαφυγή.

Παίξαμε με την μητέρα φύση! Είμαστε σε ποσοστό 60% εμβολιασμένοι. Έτσι τώρα η Δέλτα ήρθε για να μείνει μέχρι να αλλάξουν τα εμβόλια….

Πρόσφατη εργασία, που μόλις κυκλοφόρησε απ’ το Πανεπιστήμιο Davis της Καλιφόρνια, δείχνει ότι σε εμβολιασμένους και ανεμβολίαστους τα ιικά φορτία είναι υψηλά και ίδια στις δύο ομάδες.

Είναι ξεκάθαρο ότι τα εμβόλια δεν κάνουν απολύτως τίποτα για να βοηθήσουν να μειωθεί η φορεία του ιού!

Ένα εμβολιασμένο άτομο απειλεί εξίσου κάποιον που δεν έχει εμβολιαστεί και δεν έχει νοσήσει. Αυτό που μας έδειξαν ο Niesen και οι συνεργάτες του απ’ την κλινική Mayo είναι ότι μόλις ξεκινήσαμε να εμβολιάζουμε και φτάσαμε στο 25% εμβολιασμένων, η ποικιλομορφία άρχισε να πέφτει, ότι ο αριθμός των διαφορετικών στελεχών που κατηγοριοποιούσε το CDC κάθε 2 βδομάδες άρχισε να κατακρημνίζεται, επειδή αρχίσαμε να παίζουμε με την μητέρα φύση και δεν θα ‘πρεπε να το κάνουμε αυτό!!!!».

ΠΗΓΗ:https://www.pronews.gr/ygeia/1026236_drpmccullough-paixame-me-tin-mitera-fysi-oi-kyverniseis-piesan-gia-maziko-emvoliasmo

Oct 18

Ποια θα είναι η επόμενη πανδημία που ετοιμάζει το Μέγα Διευθυντήριο; Ο έμβολα, ο Nipah, ο κίτρινος πυρετός ή ο Marburg;

By Γεώργιος Ευαγγελάτος in Γενική Εξέγερση, Επιστήμη

A deadly cousin of Ebola, Marburg can kill nine out of ten people it infects, and international travel has taken it from Africa to Europe twice in the past 40 years. Will increasing globalisation make this virus more likely to erupt around the world?

In August 1967, a cluster of patients in Marburg and Frankfurt, in Germany, and in Belgrade (then Yugoslavia, now Serbia), began showing symptoms of an infectious disease – a high fever, chills, muscle ache, and vomiting. The patients worsened over the next few days, until they began bleeding from every orifice in their body, including needle puncture wounds. In total 31 people died.

Three months after this outbreak, virologists in Marburg had discovered the first filovirus, a cousin of the equally-deadly Ebola virus. The virus had been carried by infected African green monkeys from Uganda.

Avoiding handling or eating bush meat is also critical to avoid any potential infection that could spread from animals.

After this first sighting, the virus was then mostly seen in African countries, in bat-infested caves or mines. About 40 years later, however, the virus re-emerged in Europe through a traveler returning to the Netherlands from a trip to Uganda where she had been visiting caves.

The largest known outbreak of Marburg virus, in Angola in 2004, infected over 250 people and had a 90 percent fatality rate.

Marburg virus can persist in the eyes and testes of people who have recovered, and in pregnant women it can persist in the placenta and amniotic fluid as well as breast milk. This can be extremely dangerous. In early 2021, there were reports that Ebola, closely related to Marburg, could lay dormant in people only to emerge many months after an epidemic had ended, triggering another outbreak.

Disease: Marburg

Where is it circulating? Most outbreaks have been in Africa, with cases reported in Angola, the Democratic Republic of the Congo, Kenya, South Africa, Uganda and Zimbabwe. However, there have been outbreaks in Europe and the USA.

Pandemic threat: As Marburg virus can spread from human to human through contact of bodily fluids, much like Ebola. As outbreaks in Europe and the US have already shown, increasing globalisation and international travel mean that the risk for global spread is high, especially when the incubation period could be up to three weeks. This could be disastrous given its high death rate.

How is it spread? The Egyptian rousette fruit bats often harbour the virus. African green monkeys have in the past spread the virus to people in Uganda, but pigs can also become infected and can be a source of infection. Marburg virus is spread through direct contact (through broken skin or mucous membranes) with the blood, secretions, organs or other bodily fluids of infected people, and also through any materials such as bedding, that have been contaminated with the infected fluids. As a result, health workers have often become infected by treating patients with Marburg virus. Burial ceremonies in which people have direct contact with the body can also drive the spread of the virus.

Have you read?

Case fatality rate: Marburg is one of the deadliest viruses we know of, killing as many as 88% people it infects.

Incubation period: The incubation varies from as short as two days to up to 21 days, though some studies have suggested the virus can incubate for as long as 26 days.

Symptoms: Marburg virus begins with a fever, severe headache and muscle pains. This is often followed by watery diarrhoea, stomach pain, nausea and vomiting, accompanied by extreme exhaustion and lethargy. Many people go on to develop severe viral haemorrhagic fever, and in severe cases have blood in their vomit and faeces, and may bleed from their nose, gums and vagina. The onslaught of the virus is so extreme that most people die 8-9 days after infection, often because of extreme loss of blood.

Diagnosis: Marburg can be difficult to distinguish clinically from other diseases, such as malaria, typhoid fever, meningitis and other viral haemorrhagic fevers. Diagnosis can be confirmed using techniques that detect the presence of immune response to the virus, such as antibody-capture enzyme-linked immunosorbent assay (ELISA), or the presence of virus in people presenting with symptoms, via antigen-capture detection tests, reverse transcriptase polymerase chain reaction (RT-PCR) assay, or virus isolation by cell culture. However, often none of these diagnostic tools are available in the countries with highest risk of Marburg outbreaks. In addition to having the diagnostic tests available, countries need to have laboratories that can ensure maximum biological containment conditions due to the fact that the samples are an extreme biohazard risk.

Are there vaccines or treatments, or ongoing R&D?

There are currently no specific therapeutics for Marburg virus. However, supportive care including rehydration with oral or intravenous fluids can improve survival. This can mean maintaining oxygen status and blood pressure, replacing lost blood and clotting factors, and treating any complicating infections. Potential treatments, including blood products, immune therapies and drug therapies, are currently being assessed. Marburg virus vaccine candidates are being investigated, and in 2019, for example, IAVI (the International AIDS Vaccine Initiative) began researching a recombinant vesicular stomatitis virus (VSV) vector Marburg virus vaccine candidate, called rVSVΔG-MARV-GP. Another vaccine candidate MVA-BN Filo containing both Marburg and Ebola virus antigens could potentially protect against both haemorrhagic viruses. It is currently in phase 3 trials, and seems to trigger good immunity against the Ebola Zaire strain but it has not yet been tested against Marburg virus.

How could we lower the risk of it becoming a pandemic?

Since Marburg virus can spread between people, extremely stringent infection control measures are needed to avoid people being in any contact with each other, to ensure any laboratory samples are disposed of carefully, and to ensure safe burial procedures. Avoiding handling or eating bush meat is also critical to avoid any potential infection that could spread from animals. International travel is a major risk factor for the spread of Marburg virus beyond Africa and rapid diagnostics to ensure that cases are picked up before people carry the virus to other countries will be important.

For more on Marburg virus disease, here is WHO’s fact sheet: https://www.who.int/news-room/fact-sheets/detail/marburg-virus-disease

Source:https://www.gavi.org/vaccineswork/next-pandemic/marburg

Oct 17

Συνωμοσιολογία; Ο επόμενος ιός είναι έτοιμος και λέγεται Marburg. Πρόκειται για αιμορραγικό πυρετό παρόμοιο με τον Έμπολα με ποσοστό θνησιμότητας 88%.

By Γεώργιος Ευαγγελάτος in Γενική Εξέγερση

Κυρίες και Κύριοι. Θα ήθελα να προετοιμαστείτε συναισθηματικά και πνευματικά για ό,τι πρόκειται να ξεδιπλωθεί εδώ στη Γη. Είναι έτοιμοι να μας θυσιάσουν στον Μολώχ. Πιστεύετε τώρα που είδαν τι επιτυχία είχε ο COVID-19 θα σταματήσει το Παγκόσμιο Διευθυντήριο να εξαπολύει τα βιολογικά του όπλα;

Η επόμενη Πανδημία πρόκειται να είναι ο ιός Marburg. Πρόκειται για αιμορραγικό πυρετό παρόμοιο με τον Έμπολα με ποσοστό θνησιμότητας 88%. Τώρα καταρχάς μην ανησυχείτε, όσοι προωθούν αυτήν την ατζέντα δεν θα κυκλοφορήσουν τίποτα που θα τους σκότωνε. Αυτό θα είναι ψεύτικο Marburg. Πολλοί από τους τραυματίες του εμβολίου covid εμφανίζουν θρόμβους και ανεξέλεγκτη αιμορραγία. Αυτό θα ισχυριστεί ότι είναι Marburg. Το GAVI και το WEF κάνουν ήδη ανακοινώσεις σχετικά με τον ιό. Έχουν ήδη αναπτύξει ένα τεστ PCR για το Marburg, παρόλο που δεν υπάρχει ακόμη επίσημη «πανδημία». Το πιο ανησυχητικό είναι ότι ήδη σπεύδουν να βρουν ένα «εμβόλιο» για τον Marburg. Ακόμα πιο ανησυχητικό, το κύριο συστατικό του νέου εμβολίου είναι η Ρικίνη. Ένα από τα πιο τοξικά δηλητήρια στον πλανήτη. Θα επιτρέψουν στους εμβολιασμένους να ταξιδέψουν παγκοσμίως αυτά τα Χριστούγεννα. Θα χρειαστούν ένα κάλυμμα για άτομα που φέρνουν τον «ιό» πίσω στις χώρες τους. Μια νέα πανδημία θα κηρυχθεί, θα ισχυριστούν ότι υπάρχει ασυμπτωματική εξάπλωση. Τα μέσα ενημέρωσης θα εκτοξεύσουν τον φόβο πιο σκληρά από ό,τι έχουμε δει ποτέ. Οι άνθρωποι θα χάσουν το μυαλό τους πιστεύοντας ότι υπάρχει πανδημία για κάτι με πιθανότητα 88% να τους κάνει να αιμορραγήσουν και να πεθάνουν. Σε αυτό το στάδιο τα τρυπήματα θα είναι υποχρεωτικά και οι αστυνομικές και στρατιωτικές ομάδες θα είναι σε πλήρη ισχύ προσπαθώντας να «σώσουν την ανθρωπότητα» και να παρασύρουν ανθρώπους που αρνούνται το εμβόλιο του Μάρμπουργκ στα χτισμένα τώρα στρατόπεδα συγκέντρωσης για να τους κάνουν ενέσεις. Το «εμβόλιο» της Ρικίνης είναι ο πραγματικός θάνατος και θα υπάρχουν δισεκατομμύρια άνθρωποι που θα το κάνουν και θα αγωνίζονται για να βρεθούν στην πρώτη γραμμή. Αν νομίζετε ότι έχετε δει πανικό κατά τη διάρκεια του COVID, πολλαπλασιάστε το με 20 ή 30 Χ με αυτό που σχεδιάζεται και έρχεται. Κρατήστε τις οικογένειές σας κοντά.
https://threadreaderapp.com/thread/1444688482409107456.html

Γ.Ν

ΠΗΓΗ:https://www.ksipnistere.com/2021/10/blog-post_508.html

Oct 17

200 χρόνια μετά την απελευθέρωση η Γιάννα το ξεκαθαρίζει: <<Μ' ένα τσιπάκι όλα θα μπουν στη θέση τους, τελεία και παύλα>>

By Γεώργιος Ευαγγελάτος in Απόδοση Δικαιοσύνης, Γενική Εξέγερση, Επιστήμη

Μην ταράζεστε, άλλοι φροντίζουν για τον Νέο Θαυμαστό Κόσμο που θα ζήσετε και σεις και τα παιδιά σας από δω και στο εξής. Και όπως λέει ο πατέρας του χαζοβιβλίου “Great Reset” Klaus Swabb ποτέ δεν θα επιστρέψουμε στην παλιά κανονικότητα.

Μια νέα αρχή ξεκινάει για την ανθρωπότητα, ένας καθαρά σιωνιστικός μεσσιανικός τρόπος του ζειν. Όπως το έχει προβλέψει ο Ιωάννης στην “Αποκάλυψή” του και πολλοί άλλοι θεοφώτιστοι πατέρες της εκκλησίας μας όπως ο Άγιος Ανδρέας Καισαρείας, ο Άγιος Ιππόλυτος, ο Όσιος Εφραιμ ο Σύρος, Άγιος Μεθόδιος Πατάρων, κι ο Άγιος Αρέθας εκ Καισαρείας, ο Όσιος Νείλος και ο προφήτης Δανιήλ και άλλοι[1].

Τώρα μας προέκυψε και η κυρία Γιάννα Αγγελοπούλου η οποία μυημένη στις αρχές της Νέας Τάξης Πραγμάτων πολύτιμη παγκοσμιοποιήτρια, είπε αλήθειες καθόλου τυχαίες οι οποίες βρίσκονται πολύ κοντά στην πραγματοποίησή τους. ‘Ακούστε τη και χαρείτε την…

Καταλάβατε; με ένα τσιπάκι, κάνοντας σκόνη τα προσωπικά μας δεδομένα, εμάς των πληβείων εννοεί, θα λυθούν (γι’ αυτούς, το Παγκόσμιο Διευθυντήριο) όλα τα προβλήματα.

Τι άλλο περιμένετε; Τώρα το ξέρετε που θα βαδίσουν τα πράγματα αν τους αφήσετε και κοιμάσθε ύπνον βαρύ.

Γεώργιος Ευαγγελάτος

[1]Ευαγγελάτου Γεωργίου: Η ΑΠΟΚΑΛΥΨΗ ΤΟΥ ΙΩΑΝΝΗ ΑΠΟΚΑΛΥΠΤΕΤΑΙ, Εκδόσεις Στερέωμα, Θεσσαλονίκη 2005.

Oct 17

Στην Αγγλία οι πλήρως εμβολιασμένοι γεμίζουν τις κλινικές COVID-19 και το 80 με 81% πεθαίνει

By Γεώργιος Ευαγγελάτος in Επιστήμη

Official Data: Nearly All ‘Covid’ Deaths in August and September Occurred in the Fully Vaccinated

HAFOctober 11, 2021

The Office for National Statistics (ONS) in the United Kingdom has released a new dataset showing that 81 percent of everyone who died in the month of September [and 80% in August] after testing “positive” for the Wuhan coronavirus (Covid-19) was “fully vaccinated” in accordance with government guidelines.

Again, 80% of “Covid-19” deaths from AUGUST and 81% “Covid-19” deaths from SEPTEMBER. That’s huge!

official data nearly all 'covid' deaths in august and september occurred in the fully vaccinated

Bombshell update: Johns Hopkins data provides further proof that COVID shots cause the majority of illness and death around the world.

In the U.K. alone during the month of September, some 30,305 people died within 21 days of getting injected for the Chinese Flu. This was an inadvertent admission by the ONS, which had previously told inquiring minds that “they do not hold this information.”

It turns out that they do hold this information, but did not want to make it public because it wrecks the mainstream claim among governments and medical systems that Fauci Flu shots are “safe and effective.”

“The ONS report, used to dupe the public into believing just 1% of fully vaccinated people have died of Covid-19, didn’t include Covid-19 deaths that have and are currently occurring in this extremely strange third wave of Covid-19 deaths,” reported Humans Are Free.

“Strange because Covid-19 deaths have been and still are many times higher than this time last year, despite the fact summer has been on our side, as well as an allegedly 95% effective vaccine.”

One year ago, the number of covid-related deaths pretty much flat-lined. This was before Donald “father of the vaccine” Trump unleashed his rushed-to-market “Operation Warp Speed” injections, for which he is still going around bragging are one of his greatest “accomplishments.”

This year, however, the world is seeing a massive surge in new “cases” of the Chinese Virus. The numbers are so high that Humans Are Free reported that this is something “you would expect to see in the middle of winter with a 95% effective vaccine.”

Winter is coming: What will become of the fully vaccinated?

The shots are obviously not 95 percent effective, unless by “effective” they mean that these injections are injuring and killing most of the people who take them. Perhaps this is the real goal of the plandemic, which was obviously never about “saving lives” of “flattening the curve” – unless human beings are the “curve,” of course.

In that case, the world population really is being flattened at warp speed, and millions remain none the wiser due to their willful ignorance and blind trust in the system to somehow have their best interests in mind.

Not only are the vast majority of all “covid” deaths now occurring among the fully vaccinated, but so are the vast majority of all new “cases.” Pretty much the only people still having trouble with Chinese Germs are those who took the jabs, in other words.

Week after week, hospitals are filling up with fully jabbed people who are getting sick and dying in droves due to their immune systems being wrecked by spike proteins and whatever other poisons are contained within those mystery vials.

This is data that anyone can look at, by the way. Anyone who claims to support “science” is lying to themselves if they continue to believe the likes of Tony Fauci and CNN when it comes to the “new normal” of widespread Chinese Virus vaccination compliance.

“The data clearly shows the jabs do not prevent infection or transmission, and it clearly shows that even in summer and early autumn they are increasing the risk of hospitalisation and death rather than reducing the risk,” reports Humans Are Free, noting that this is all happening in summer when sickness and death should be at a minimum.

“The problem we now face? Winter is just around the corner.”

ΠΗΓΗ:https://humansarefree.com/2021/10/nearly-all-covid-deaths-occurring-in-fully-vaccinated.html

Oct 17

Συνήθεις ερωτήσεις γύρω από τα 4 εμβόλια και μάλλον αφελείς απαντήσεις που επιδιώκουν να καθησυχάσουν τους ερωτώντες

By Γεώργιος Ευαγγελάτος in Επιστήμη

It’s my understanding that the risk of myocarditis from the vaccine is higher than the risk of hospitalisation from Covid, so why should I put my child through a painful procedure with awful side effects? Kim Briscoe

Philippa Roxby Health reporter

Myocarditis is a very rare side effect of the Pfizer and Moderna vaccines. Symptoms – which can include chest pain or palpitations – go away quickly. For every million first doses, there have been between three and 17 cases, with more occurring in boys than girls. Very few have ended up in hospital.

But these heart symptoms can also be caused by Covid-19 itself, and a tiny number of children do end up seriously ill from the virus, including long-lasting symptoms.

According to figures from the JCVI – the government’s vaccination advisers – vaccinating one million children would prevent 87 hospital admissions and two intensive care admissions.

Getting the vaccine itself is virtually painless and most children will only have a slightly sore arm afterwards.

How will my son having the vaccine prevent disruption to education? Elizabeth Allcock

Nick Triggle Health correspondent

There’s a reason this decision-making process has been so painful – it is such a finely balanced call.

Healthy children aged 12 to 15 are at such low risk from Covid, that the benefit of vaccination on health grounds alone is only marginal.

Even in terms of limiting school disruption, the modelling suggests the benefits may only be small.

The emergence of the Delta variant means the vaccines are less effective at preventing infection than they once were.

As a mother of teenage girls, I am worried about the potential long-term impact on their fertility. Anecdotally I have a number of female friends and relatives whose periods have been affected by their Covid jabs, so what impact is it having on our reproductive system? Emma, Coventry

Philippa Roxby Health reporter

Some women have reported changes to their periods, such as unusually heavy bleeding, or that they’ve stopped for a while – and experts say there’s a logical explanation for that.

After vaccination, immune cells are affected, the body’s defence system fires up and there’s an inflammatory response – which could all cause menstrual changes. The flu and HPV vaccines can also have the same effect.

But doctors say there are no long-term side effects and women shouldn’t be worried.

There has been lots of misinformation on social media around the vaccines and fertility – but don’t believe anything that has not been written by a gynaecological specialist. Experts all say there is no way the vaccines could have an impact on fertility. In fact, getting Covid itself is more likely to cause a variety of health issues which could affect fertility.

The vaccines have also been recommended for use in pregnancy.

Why is the AstraZeneca vaccine not being used as a booster? Stephen Cannie, Peterborough

Fergus Walsh Medical editor

The Oxford-AstraZeneca vaccine has been deemed safe and effective to use as a booster, but is only being recommended for people who are allergic to the mRNA vaccines (Pfizer and Moderna).

I understand that concern about a rare blood clotting side effect is the reason why the AZ vaccine is not being used as a booster. For this reason it is already limited in the UK to those over 40.

All the vaccines used in the UK provide significant defences against severe Covid. But it remains unclear which will offer the most lasting protection. Pfizer and Moderna score best in the initial weeks after immunisation, but their immunity wanes more quickly than the AstraZeneca vaccine, which uses a disabled virus.

So it would be wrong to completely write off the Oxford-AZ jab as a booster. If the vaccine is shown to give more durable immunity, it may yet have a continuing role here.

I am a 72-year-old man and I was wondering if it’s possible to get the booster and flu jabs at the same time? Dennis, Fife

Yes. When it announced its programme of booster jabs, the Scottish government said it would follow the advice of the JCVI and “wherever possible, eligible people will be offered Covid-19 and flu vaccines together”.

As an over-50, you are in one of the groups who will be offered a Covid booster. Other groups include frontline health and social care workers, people aged 16 to 49 with underlying health conditions, and older adults in residential care homes. This last group will start receiving both jabs in Scotland in the next week.

Making a similar announcement for England, Deputy Chief Medical Officer Jonathan Van-Tam said that people who are eligible for the Covid booster would also be offered the flu vaccine at the same time, although this may not always be practically possible.

Northern Ireland and Wales also intend to make both jabs available together, although in Wales, health minister Eluned Morgan cautioned that it would be “only where timing and logistics allow”.

We’re told the number of new infections every day, but we’re never told how many of them are people who have already been fully vaccinated. Why not? Sherwin Smith, Wallingford

Robert Cuffe Head of statistics

Public Health England (PHE) has now started to release this data.

Earlier this month it published estimates of the rates of case numbers in vaccinated and unvaccinated people.

It’s tempting to compare these case numbers directly, but it also can be very misleading.

Vaccinated people are more likely to be old, white, well-off or clinically vulnerable than the population at large. So you might end up learning a bit about the effect of being old or well-off rather than the effect of being vaccinated.

That’s why scientists tend to rely on carefully conducted studies that compare case rates in vaccinated people with the case rates in otherwise similar unvaccinated people.

Is it worth taking a low dose of aspirin to thin the blood at the time of vaccination to reduce the risk of blood clots? From Ranmali Fernando, Enfield

For anyone not already prescribed aspirin by a doctor, Professor Beverly Hunt, medical director of Thrombosis UK, strongly advises against this.

“We know if you take aspirin and you don’t need to take aspirin, the benefits aren’t very good,” she told the BBC.

However, anyone who has already been prescribed aspirin by a doctor should continue to take it before their jab, says blood specialist Prof Adrian Newland.

Anyone on anti-coagulant medicines (such as Warfarin) – or people who have clotting disorders – should speak to their doctors before having the jab, he says. They should also let vaccinators know about any blood thinning medications.

What are the signs you may be developing a blood clot? From Lindsey Handley, Caterham, Surrey

Doctors are focusing on several types of blood clots regarding the Oxford-AstraZeneca vaccine.

One that has attracted particular attention is a clot on the brain called Cerebral Venous Sinus Thrombosis (CSVT).

It forms in large veins in the head – stopping blood from draining out of the brain. As a result, blood cells may break and leak into brain tissue – ultimately leading to a stroke.

CVSTs are more common, but still very rare, in younger women.

If you suspect you or someone else is having a stroke, you should call 999.

The UK’s medicines regulator – the MHRA – says anyone who has the following symptoms four or more days after receiving the AstraZeneca vaccine should seek prompt medical advice: severe or persistent headache, blurred vision, chest pain, shortness of breath, swollen legs, persistent abdominal pain, unusual skin bruising, pinpoint spots (not including the injection site).

How long after a vaccine can the rare blood clot develop? If it is three weeks since my jab, am I definitely in the clear? From Rushda Khan, Cambridge

Most cases have been seen between four days and a few weeks after people have had their jab.

Medical experts in the UK suggest doctors should consider this rare condition as a possible diagnosis for anyone who has matching symptoms up to a month after they have had the vaccine.

If you had your vaccine three weeks ago, you should seek medical advice if you experience any of the symptoms listed above in the next week or so.

As a mother of teenage girls, I am worried about the potential long-term impact on their fertility. Anecdotally I have a number of female friends and relatives whose periods have been affected by their Covid jabs, so what impact is it having on our reproductive system? Emma, Coventry

Philippa Roxby Health reporter

Some women have reported changes to their periods, such as unusually heavy bleeding, or that they’ve stopped for a while – and experts say there’s a logical explanation for that.

After vaccination, immune cells are affected, the body’s defence system fires up and there’s an inflammatory response – which could all cause menstrual changes. The flu and HPV vaccines can also have the same effect.

But doctors say there are no long-term side effects and women shouldn’t be worried.

The vaccines have also been recommended for use in pregnancy.

Is the risk of clotting higher in young women currently taking the birth control pill? From Karen, Gateshead

Pregnancy, the combined pill and some fertility treatments have been known to put people at higher risk of clots in general. Some of these clots can be treated more easily than CVSTs.

The European Medicines Agency estimates that for every 10,000 women using combined hormonal contraception for a year, between five and 12 will develop clots in veins (such as deep vein thrombosis or clots to the lungs).

This compares to around two per 10,000 among people not using these types of contraception.

Experts recommend that otherwise well people should not stop taking the pill when having a vaccine.

The Royal College of Obstetricians and Gynaecologists is seeking further guidance from regulators about pregnant women and those starting fertility treatment. In the meantime, pregnant women are advised to discuss the benefits and risks of having the vaccine with their doctors.

I’m 22 years old and have had both my AstraZeneca vaccinations. What does this mean for me? From Kieran, Scotland

Since you have already had both your vaccines, you will not be affected by the decision to offer under-30s an alternative vaccine in the future.

If you have already received both doses, you might be in one of the priority groups for whom getting or spreading Covid could be especially dangerous.

People in the highest priority groups might be offered an extra booster Covid vaccine later in the year – similar to the annual flu jab which medically vulnerable patients are advised to have.

It is possible under-30s might not be offered an Astra-Zeneca booster if one is available, but we don’t know enough at this stage to be certain.

If I’ve had two vaccinations will I still need to take advantage of the free lateral flow tests being made available? From Elizabeth Woodward, Poole, Dorset

Yes. All the available data suggests the main vaccines currently in use are very effective at protecting people from becoming seriously ill – and in the majority of cases stopping people from developing symptoms at all.

However, no vaccine works for everybody who takes it, and so people should not think that just because they have had two doses of vaccine they are 100% safe – either from developing symptoms, or spreading the virus to other people they come into contact with.

Everyone in England can now get two lateral flow rests per week from testing sites, pharmacies, or through the post.

The government hopes that widening access to testing for people who don’t have symptoms will help stop outbreaks as lockdown is lifted.

How safe is the vaccine for young adults with Down’s syndrome? Jane Chatfield

The vaccines available for Covid are considered extremely safe and there are no reports of serious side-effects.

People over the age of 18 with Down’s syndrome were among the first to be vaccinated as they are on the list of those considered to be extremely clinically vulnerable.

The list was amended in November, after studies suggested people with Down’s syndrome were at greater risk of becoming seriously ill if they caught Covid.

The vast majority of children and teenagers with Down’s syndrome are considered to be at less risk than adults, although teenagers aged 16-18 have now been offered the vaccine.

Can I have the vaccine safely if I am allergic to penicillin? From James, Bristol

Michelle Roberts Health online editor

Yes. Allergy to penicillin is not listed as a clinical reason to avoid having either the Pfizer-BioNTech or the AstraZeneca-Oxford Covid-19 vaccine.

However, when you are invited for your Covid vaccine, you should discuss your allergies with healthcare staff to make sure there is no other reason to avoid it.

How do staff know that the vaccine they are giving you has not expired because of incorrect storage? From Keith, Loughborough

Philippa Roxby Health reporter

Every vial, which contains several vaccine doses, is stored frozen and has to be thawed and then diluted before people are vaccinated.

Healthcare staff will be given detailed information on exactly how long the vials can be stored in a fridge (five days) and when they should be discarded after being taken out.

Prof Jonathan Van Tam says these considerations make this “delicate” vaccine more complicated to get to people in care homes and to the elderly in their own homes.

But this won’t be as much of an issue in hospitals where vaccine doses can be stored in bulk and used quickly on staff and patients.

Will the vaccine last for the rest of your life, or will you have to have a vaccine every 12 months, like the flu jab? From Robert Parker, Warwickshire

Michelle Roberts Health online editor

It’s not clear yet how long immunity might last after vaccination.

It is possible that people will need to be vaccinated annually or every few years to have protection.

Is the vaccine compulsory? From Kim, North Yorkshire

Philippa Roxby Health correspondent

No, people in the UK are not being told they must have the vaccine.

However, those in the most at-risk groups (over-70s and care home residents), and people who work in care homes and for the NHS will be expected to have it – to protect themselves and the people they care for.

Making a vaccine mandatory is not usually recommended because it can lower confidence in the jab.

How many covid patients have long covid and what is the maximum time of the illness? From Bryan Thornton

Michelle Roberts Health online editor

It’s estimated about one in 10 people who fall ill with covid remain unwell two months after being infected. Long covid can last from weeks to many months.

Some people who were infected towards the beginning of the pandemic still have long covid now. Others have since recovered.

The symptoms of long covid are varied and can fluctuate. Doctors are learning more about the condition, including the symptoms that people may experience and how long these can last for.

Should I be washing my hair as well as my hands when I come home from outside (heavy breathing joggers passing me, supermarkets etc)? Asme Sheikh, London

On balance, this is almost certainly unnecessary.

While hand washing is very important for personal hygiene, none of the advice from the world’s leading health bodies – the World Health Organization for example, the CDC in the US or the NHS in the UK – places any importance on hair washing one way or another.

It’s theoretically possible that you could catch the virus if someone sneezed on your hair and those droplets found their way to your eyes, nose or mouth (for instance if your hair fell over your face).

However, research suggests that while virus droplets can survive for a couple of hours on some non-porous surfaces such as steel, there are few – if any – cases of Covid which can be traced back to being transmitted in this way.

I am breastfeeding my five-month-old baby – what should I do if I get coronavirus? from Maeve McGoldrick

James Gallagher Health correspondent

Mothers pass on protection from infection to their babies through their breast milk.

If your body is producing antibodies to fight the infection, these would be passed on through breastfeeding.

Breastfeeding mums should follow the same advice as anyone else over reducing risk – cover your mouth when you sneeze and cough, throw away used tissues straight away and wash hands frequently, while trying to avoid touching your eyes, nose or mouth with unwashed hands.

Can Covid-19 be transmitted through someone’s exhaled cigarette smoke/vaping? From Michael, Chichester, West Sussex

Yes. It is possible to become infected by breathing in somebody else’s second-hand smoke or exhaled vapour – both of which can transport coronavirus particles on microscopic droplets of water vapour exhaled from the lungs.

In fact, the risk could even be heightened – with some scientists believing the virus might travel considerably further this way than when exhaled in normal breath.

However, a study found that the increased risk of virus transmission for the majority of vapers was much less than the increased risk from talking or coughing.

Government guidance for smokers says it’s difficult to gauge the risk to individuals – and, in the absence of specific evidence, recommends that vapers err on the side of caution and avoid breathing out clouds of vapour in the presence of others.

When venues reopen in England, they will be prohibited from providing smoking equipment – such as shisha pipes – for use on the premises.

Source: https://www.bbc.com/news/world-asia-

Καλώς Ήλθατε

O Γιώργος Ευαγγελάτος ψυχίατρος – ψυχαναλυτής παρέχει ψυχιατρική βοήθεια και συμβουλευτική σε ανθρώπους που αντιμετωπίζουν προσωπικές ή οικογενειακές ψυχολογικές και ψυχοκοινωνικές δυσκολίες. Μάθετε περισσότερα για εμάς εδώ.

Notable features of the SARS-CoV-2 genome

1. Mutations in the receptor-binding domain of SARS-CoV-2

2. Polybasic furin cleavage site and O-linked glycans

Theories of SARS-CoV-2 origins

1. Natural selection in an animal host before zoonotic transfer

2. Natural selection in humans following zoonotic transfer

3. Selection during passage

Conclusions

References

Acknowledgements

Author information

Affiliations

Corresponding author

Ethics declarations

Competing interests

Rights and permissions

SARS-CoV-2 mass vaccination: Urgent questions on vaccine safety that demand answers from international health agencies, regulatory authorities, governments and vaccine developers

Abstract

Introduction

SARS-CoV-2 phase 3 trial exclusion criteria

Will serious adverse effects from the SARS-CoV-2 vaccines go unnoticed?

Unanticipated adverse reactions to SARS-CoV-2 vaccines

Discussion

Conflict of Interest Statement

References

Figure legends

Dr.P.McCullough: «Παίξαμε με την μητέρα φύση – Οι κυβερνήσεις πίεσαν για μαζικό εμβολιασμό και “αχρήστεψαν” τα εμβόλια»

The next pandemic: Marburg?

Avoiding handling or eating bush meat is also critical to avoid any potential infection that could spread from animals.

Disease: Marburg

Have you read?

Are there vaccines or treatments, or ongoing R&D?

How could we lower the risk of it becoming a pandemic?

For more on Marburg virus disease, here is WHO’s fact sheet: https://www.who.int/news-room/fact-sheets/detail/marburg-virus-disease

Official Data: Nearly All ‘Covid’ Deaths in August and September Occurred in the Fully Vaccinated

Winter is coming: What will become of the fully vaccinated?

As a mother of teenage girls, I am worried about the potential long-term impact on their fertility. Anecdotally I have a number of female friends and relatives whose periods have been affected by their Covid jabs, so what impact is it having on our reproductive system? Emma, Coventry

Καλώς Ήλθατε

Πρόσφατα Άρθρα

Αρχείο Αναρτήσεων

Ημερολόγιο Αναρτήσεων

Πρόσφατα Σχόλια

Ετικέτες

Categories

Meta